The DOI matches its Crossref record.
A Comparison between Two Strategies for Monitoring Hepatic Function during Antituberculous Therapy
Abstract
Rationale: The optimum strategy for monitoring liver function during antituberculous therapy is unclear. Objectives: To assess the value of the American Thoracic Society risk-factor approach for predicting drug-induced liver injury and to compare with a uniform policy of liver function testing in all patients at 2 weeks. Methods: We conducted an observational study of adult patients undergoing therapy for active tuberculosis at a tertiary center. All patients had alanine transferase measurement at baseline and 2 weeks following commencement of therapy. Sensitivity, specificity, and positive and negative predictive values were used to assess strategies. Measurements and Main Results: There were 288 patients included, and 21 (7.3%) developed drug-induced liver injury (57.1% “early” at 2 wk and 42.9% “late,” after 2 wk). There were increased rates of individuals with HIV infection in the early drug-induced liver injury group compared with no drug-induced liver injury and late drug-induced liver injury groups (33% vs. 7.1% vs. 0%; P = 0.004). The American Thoracic Society algorithm had a sensitivity and specificity of 66.7 and 65.6%, respectively, for prediction of early and 22.2% and 63.7% for late drug-induced liver injury. The uniform monitoring policy had poor sensitivity but better specificity (22.2 and 82.1%) for prediction of late drug-induced liver injury. Conclusions: In our urban, ethnically diverse population, a risk-factor approach is neither sensitive nor specific for prediction of drug-induced liver injury. A uniform policy of liver function testing at 2 weeks is useful for prompt identification of a subgroup who develop early drug-induced liver injury and may offer better specificity in ruling out late drug-induced liver injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Underreporting and poor adherence to American Thoracic Society guidelines are common in cases of isoniazid hepatotoxicity and are associated with hospitalization, death, and liver transplantation.187,188”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [187]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 32
- Ormerod, 1996, Frequency and type of reactions to antituberculosis treatment: an 11 year study, Tuber Lung Dis, 77, 335, 10.1016/S0962-8479(96)90073-8 · DOI
- Yee, 2003, Incidence of serious side effects from first line antituberculosis drugs among patients treated for active tuberculosis, Am J Respir Crit Care Med, 167, 1472, 10.1164/rccm.200206-626OC · DOI · Paper page
- Sharifzadeh, 2005, Evaluation of patient-related factors associated with causality, preventability and severity of hepatotoxicity during antituberculosis treatment, Pharmacol Res, 51, 353, 10.1016/j.phrs.2004.10.009 · DOI
- Schaberg, 1996, Risk factors for side-effects of isoniazid, rifampicin and pyrazinamide in patients hospitalized for pulmonary tuberculosis, Eur Respir J, 9, 2026, 10.1183/09031936.96.09102026 · DOI · Paper page
- Sharma, 2002, Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment, Am J Respir Crit Care Med, 166, 916, 10.1164/rccm.2108091 · DOI · Paper page
- Van Hest, 2004, Hepatotoxicity of rifampicin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment, Clin Infect Dis, 39, 488, 10.1086/422645 · DOI · Paper page
- Breen, 2006, Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection, Thorax, 61, 791, 10.1136/thx.2006.058867 · DOI · Paper page
- Tost, 2005, Severe hepatotoxicity due to anti-tuberculosis drugs in Spain, Int J Tuberc Lung Dis, 9, 534
- Saukkonen, 2006, An official ATS Statement: hepatotoxicity of antituberculosis therapy, Am J Respir Crit Care Med, 174, 935, 10.1164/rccm.200510-1666ST · DOI · Paper page
- Tostmann, 2008, Antituberculosis drug-induced hepatotoxicity: concise up-to date review, J Gastroenterol Hepatol, 23, 192, 10.1111/j.1440-1746.2007.05207.x · DOI · Paper page
- Black, 1975, Isoniazid-associated hepatitis in 144 patients, Gastroenterology, 69, 289, 10.1016/S0016-5085(19)32568-5 · DOI · Paper page
- Agal, 2005, Monitoring and management of antituberculosis drug induced hepatotoxicity, J Gastroenterol Hepatol, 20, 1745, 10.1111/j.1440-1746.2005.04048.x · DOI
- McNeill, 2003, Pyrazinamide and rifampicin vs isoniazid for the treatment of latent tuberculosis, Chest, 123, 102, 10.1378/chest.123.1.102 · DOI
- Thompson, 1995, Anti-tuberculosis medication and the liver: dangers and recommendations in management, Eur Respir J, 8, 1384, 10.1183/09031936.95.08081384 · DOI
- Ormerod, 1996, Hepatotoxicity of antituberculosis drugs, Thorax, 51, 111, 10.1136/thx.51.2.111 · DOI
- Wu, 1990, Isoniazid-rifampicin induced hepatitis in hepatitis B carriers, Gastroenterology, 98, 502, 10.1016/0016-5085(90)90846-S · DOI
- Wong, 2000, Antituberculous drug-related liver dysfunction in chronic hepatitis B infection, Hepatology, 31, 201, 10.1002/hep.510310129 · DOI · Paper page
- Hwang, 1997, A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B, J Gastroenterol Hepatol, 12, 87, 10.1111/j.1440-1746.1997.tb00353.x · DOI
- Ungo, 1998, Anti-tuberculosis drug induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus, Am J Respir Crit Care Med, 157, 1871, 10.1164/ajrccm.157.6.9711039 · DOI · Paper page
- Nader, 2010, Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor?, Ann Hepatol, 9, 70, 10.1016/S1665-2681(19)31682-5 · DOI
- Chien, 2010, Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment, Int J Tuberc Lung Dis, 14, 616
- Possuelo, 2008, Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil, Eur J Clin Pharmacol, 64, 673, 10.1007/s00228-008-0484-8 · DOI
- Dossing, 1996, Liver injury during anti-tuberculosis treatment: an 11 year study, Tuber Lung Dis, 77, 335, 10.1016/S0962-8479(96)90098-2 · DOI
- Pande, 1996, Risk factors for hepatotoxicity from antituberculosis drugs: case-control study, Thorax, 51, 132, 10.1136/thx.51.2.132 · DOI · Paper page
- Pessayre, 1977, Isoniazid-rifampicin fulminant hepatitis, Gastroenterology, 72, 284, 10.1016/S0016-5085(77)80088-7 · DOI
- Ozick, 1995, Hepatotoxicity from isoniazid and rifampin in inner city AIDS patients, Am J Gastroenterol, 90, 1978
- Walker, 2009, Hepatotoxicity and antituberculosis therapy: time to revise UK guidance?, Thorax, 64, 918, 10.1136/thx.2009.115469 · doi:10.1136/thx.2009.115469
- Durand, 1996, Hepatotoxicity of antitubercular treatments: rationale for monitoring liver status, Drug Saf, 15, 394, 10.2165/00002018-199615060-00004 · DOI
- Riska, 1976, Hepatitis cases in isoniazid treated groups and in a control group, Bull Int Union Tuberc, 51, 203
- Seneratne, 2006, Anti-tuberculosis drug induced hepatitis – a Sri Lankan experience, Ceylon Med J, 51, 9, 10.4038/cmj.v51i1.1369 · doi:10.4038/cmj.v51i1.1369
- Baghaei, 2010, Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases, Am J Ther, 17, 17, 10.1097/MJT.0b013e31818f9eae · DOI
- Chaudhry, 2011, Racial disparities in health literacy and access to care among heart failure patients, J Card Fail, 17, 122, 10.1016/j.cardfail.2010.09.016 · DOI
Cited by
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
“Underreporting and poor adherence to American Thoracic Society guidelines are common in cases of isoniazid hepatotoxicity and are associated with hospitalization, death, and liver transplantation.[187,188] However, when patients are educated to self‐monitor and stop drugs when symptoms occur, ALF and death can be aver…”
BackgroundDrug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines
Devarbhavi, H., Aithal, G., Treeprasertsuk, S., Takikawa, H., Mao, Y., Shasthry, S. M., Hamid, S., Tan, S. S., Philips, C. A., George, J., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10144-3 · Cited by 181
Abbara, A., Chitty, S., Roe, J. K., Ghani, R., Collin, S. M., Ritchie, A., Kon, O. M., Dzvova, J., Davidson, H., Edwards, T. E., et al. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2330-z · Cited by 100
Self-citationDevarbhavi, H., Singh, R., Patil, M., Sheth, K., Adarsh, C. K., & Balaraju, G. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2012.07279.x · Cited by 86
Metadata
- Authors
- Singanayagam, A., Sridhar, S., Dhariwal, J., Abdel-Aziz, D., Munro, K., Connell, D. W., George, P. M., Molyneaux, P. L., Cooke, G. S., Burroughs, A. K., Lalvani, A., Wickremasinghe, M., & Kon, O. M.
- Affiliations
- Department of Respiratory Medicine, St. Mary's Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom
- Tuberculosis Research Unit, National Heart and Lung Institute, and
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-03
- Volume
- 185
- Issue
- 6
- Pages
- 653-659
- ISSN
- 1073-449X
- 1535-4970
- Cited by
- 47
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Comparison between Two Strategies for Monitoring Hepatic Function during Antituberculous Therapy. https://app.cochat.ai/papers/10.1164/rccm.201105-0850oc
- The paper
- Singanayagam, A., Sridhar, S., Dhariwal, J., Abdel-Aziz, D., Munro, K., Connell, D. W., George, P. M., Molyneaux, P. L., Cooke, G. S., Burroughs, A. K., Lalvani, A., Wickremasinghe, M., & Kon, O. M. (2012). A Comparison between Two Strategies for Monitoring Hepatic Function during Antituberculous Therapy. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201105-0850oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.